Monopar Therapeutics announces preclinical imaging data for MNPR-101

Monopar Therapeutics announced positive preclinical imaging data of a therapeutic radioisotope bound to its proprietary uPAR targeting agent MNPR-101. The data clearly demonstrate highly preferential uptake in the tumor. This is an extension of the tumor imaging and efficacy data Monopar released on February 22, where Monopar disclosed biodistribution data with a diagnostic imaging radioisotope as well as efficacy data with therapeutic radioisotopes bound to MNPR-101 in human tumor xenograft models. The new imaging data released today provide additional support for the tumor-targeting ability of MNPR-101 and help explain the near complete elimination of tumors observed after a single injection of therapeutic radioisotopes bound to MNPR-101. “Some of the most aggressive, deadly cancers express uPAR, such as triple negative breast cancer and pancreatic cancer,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer. “These data further support the potential of a MNPR-101 based radiopharmaceutical to provide a very meaningful clinical benefit to patients with uPAR-positive tumors.”